Download PDF
Z Gastroenterol 2021; 59(04): 366-370
DOI: 10.1055/a-1442-9820
Mitteilungen der DGVS

Stellungnahme der AIO, DGHO und DGVS zur Nutzenbewertung von Avapritinib bei gastrointestinalen Stromatumoren (GIST)

› Further Information
Also available at
    Permissions and Reprints

1. Zusammenfassung

Diese frühe Nutzenbewertung von Avapritinib (Ayvakyt®) ist das erste Verfahren zu einem neuen Arzneimittel bei gastrointestinalen Stromatumoren (GIST). Avapritinib ist zugelassen zur Therapie von Patienten mit inoperablen oder metastasierten GIST und Nachweis einer PDGFRA-D842V-Mutation. Aufgrund des Orphan-Drug-Status wurde der Bericht vom G-BA erstellt. Subgruppen, zweckmäßige Vergleichstherapie sowie die unterschiedlichen Bewertungsvorschläge sind in [Tab. 1] zusammengefasst.



Publication History

Article published online:
12 April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Gastrointestinale Stromatumore. Onkopedia Leitlinien von DGHO, OeGHO, SGMO und SGH+SSH, Status, April 2019. https://www.onkopedia.com/de/onkopedia/guidelines/gastrointestinale-stromatumoren-gist/@@guideline/html/index.html
    PubMedGoogle Scholar
  • 2 Falkenhorst J, Hamacher R, Bauer S. New therapeutic agents in gastrointestinal stromal tu- mours. Curr Opin Oncol 2019; 31: 322-328 . doi:10.1097/CCO.0000000000000549
    CrossrefPubMedGoogle Scholar
  • 3 Hirota S. et al Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580 . doi:10.1126/science.279.5350.577
    CrossrefPubMedGoogle Scholar
  • 4 Heinrich MC. et al Kinase mutations and imatinib response in patients with metastatic gastroin- testinal stromal tumor. J. Clin. Oncol 2003; 21: 4342-4349 . doi:10.1200/JCO.2003.04.190
    CrossrefPubMedGoogle Scholar
  • 5 Pogorzelski M, Falkenhorst J, Bauer S. Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments. Curr Opin Oncol 2016; 28: 331-337 . doi:10.1097/CCO.0000000000000303
    CrossrefPubMedGoogle Scholar
  • 6 Verweij J, Judson I, van Oosterom A. STI571: a magic bullet?. Eur. J. Cancer 2001; 37: 1816-1819 . doi:10.1016/s0959-8049(01)00237-4
    CrossrefPubMedGoogle Scholar
  • 7 Demetri GD. et al Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med 2002; 347: 472-480 . DOI:10.1056/NEJMoa020461
    CrossrefPubMedGoogle Scholar
  • 8 Verweij J. et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc Am Soc Clin Oncol 2003; 22: 3272-3272
    PubMedGoogle Scholar
  • 9 Blanke CD. et al Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol 2008; 26: 626-632 . doi:10.1200/JCO.2007.13.4452
    CrossrefPubMedGoogle Scholar
  • 10 Blanke CD. et al Long-term results from a randomized phase II trial of standard- versus higher- dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol 2008; 26: 620-625 . doi:10.1200/JCO.2007.13.4403
    CrossrefPubMedGoogle Scholar
  • 11 Heinrich MC. et al Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-4774 . doi: 10.1200/JCO.2006.06.2265
    CrossrefPubMedGoogle Scholar
  • 12 Demetri GD. et al Efficacy and safety of sunitinib in patients with advanced gastrointestinal stro- mal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338 . doi:10.1016/S0140-6736(06)69446-4
    CrossrefPubMedGoogle Scholar
  • 13 Demetri GD. et al Efficacy and safety of regorafenib for advanced gastrointestinal stromal tu- mours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, pla- cebo-controlled, phase 3 trial. Lancet 2013; 381: 295-302 . doi:10.1016/S0140-6736(12)61857-1
    CrossrefPubMedGoogle Scholar
  • 14 Yoo C. et al Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha- Mutated Gastrointestinal Stromal Tumors. Cancer Res Treat 2016; 48: 546-552 . doi:10.4143/crt.2015.015
    CrossrefPubMedGoogle Scholar
  • 15 Heinrich MC. et al PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710 . doi:10.1126/science.1079666
    CrossrefPubMedGoogle Scholar
  • 16 Corless CL. et al PDGF PDGFRA mutations in gastrointestinal stromal tumors: frequency, spec- trum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-5364 . doi:10.1200/JCO.2005.14.068
    CrossrefPubMedGoogle Scholar
  • 17 Cassier PA. et al Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012; 18: 4458-4464 . doi:10.1158/1078-0432.CCR-11-3025
    CrossrefPubMedGoogle Scholar
  • 18 Grunewald S. et al. Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. Cancer Discov 2020; DOI: 10.1158/2159- 8290.CD-20-0487.
    CrossrefPubMedGoogle Scholar
  • 19 Evans EK. et al A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med 2017; 9: 414 . doi:10.1126/scitranslmed.aao1690
    PubMedGoogle Scholar
  • 20 Heinrich MC. et al Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tu- mour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 2020; 21: 935-946 . DOI: 10.1016/S1470-2045(20)30269-2
    CrossrefPubMedGoogle Scholar
  • 21 Jones RL. et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointesti- nal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer 2021; 145: 132-142
    CrossrefPubMedGoogle Scholar
  • 22 Cherny NI, Sullivan R, Dafni U. et al A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573 . doi:10.1093/annonc/mdv249
    CrossrefPubMedGoogle Scholar
  • 23 Cherny NI, Dafni U, Bogaerts J. et al ESMO-Magnitude of Clinical Benefit Scale version1.1. Ann Oncol 2017; 28: 2340-2366 . doi:10.1093/annonc/mdx310
    CrossrefPubMedGoogle Scholar